Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials
Karen Kelly, Jeffrey R Infante, Matthew H Taylor, Manish R Patel, Deborah J Wong, Nicholas Iannotti, Janice M Mehnert, Anja H Loos, Helga Koch, Isabell Speit, James L Gulley, Karen Kelly, Jeffrey R Infante, Matthew H Taylor, Manish R Patel, Deborah J Wong, Nicholas Iannotti, Janice M Mehnert, Anja H Loos, Helga Koch, Isabell Speit, James L Gulley
Abstract
Background: Antibodies targeting the programmed death-ligand 1 (PD-L1)/programmed cell death protein 1 (PD-1) checkpoint may cause adverse events (AEs) that are linked to the mechanism of action of this therapeutic class and unique from those observed with conventional chemotherapy.
Methods: Patients with advanced solid tumors who were enrolled in the phase 1 JAVELIN Solid Tumor (1650 patients) and phase 2 JAVELIN Merkel 200 (88 patients) trials received avelumab, a human anti-PD-L1 IgG1 antibody at a dose of 10 mg/kg every 2 weeks. Treatment-related AEs (TRAEs) were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0). In post hoc analyses, immune-related AEs (irAEs) were identified via an expanded AE list and medical review, and infusion-related reactions (IRRs) occurring ≤2 days after infusion and symptoms occurring ≤1 day after infusion and resolving ≤2 days after onset were identified based on prespecified Medical Dictionary for Regulatory Activities (MedDRA) terms.
Results: Of the 1738 patients analyzed, grade ≥3 TRAEs occurred in 177 (10.2%); the most common were fatigue (17 patients; 1.0%) and IRR (10 patients; 0.6%). TRAEs led to discontinuation in 107 patients (6.2%) and death in 4 patients (0.2%). Grade ≥3 irAEs occurred in 39 patients (2.2%) and led to discontinuation in 34 patients (2.0%). IRRs or related symptoms occurred in 439 patients (25.3%; grade 3 in 0.5% [9 patients] and grade 4 in 0.2% [3 patients]). An IRR occurred at the time of first infusion in 79.5% of 439 patients who had an IRR, within the first 4 doses in 98.6% of 439 patients who had an IRR, and led to discontinuation in 35 patients (2.0%).
Conclusions: Avelumab generally was found to be well tolerated and to have a manageable safety profile. A minority of patients experienced grade ≥3 TRAEs or irAEs, and discontinuation was uncommon. IRRs occurred mainly at the time of first infusion, and repeated events were infrequent. Cancer 2018;124:2010-7. © 2018 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Keywords: JAVELIN; avelumab; immunotherapy; programmed death-ligand 1 (PD-L1); safety.
© 2018 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.
Figures
References
- Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33:1974‐1982.
- Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51‐60.
- Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the practitioner. J Clin Oncol. 2015;33:2092‐2099.
- Heery CR, O'Sullivan‐Coyne G, Madan RA, et al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose‐escalation trial. Lancet Oncol. 2017;18:587‐598.
- Merck KGaA . Bavencio (avelumab) injection [package insert]. Darmstadt, Germany: Merck KGaA; 2017.
- Merck KGaA . Bavencio (avelumab) injection [summary of product characteristics]. Darmstadt, Germany: Merck KGaA; 2017.
- Gulley JL, Rajan A, Spigel DR, et al. Avelumab for patients with previously treated metastatic or recurrent non‐small‐cell lung cancer (JAVELIN Solid Tumor): dose‐expansion cohort of a multicentre, open‐label, phase 1b trial. Lancet Oncol. 2017;18:599‐610.
- Apolo AB, Infante JR, Balmanoukian A, et al. Avelumab, an anti‐programmed death‐ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase 1b study. J Clin Oncol. 2017;35:2117‐2124.
- Chung HC, Arkenau HT, Wyrwicz L, et al. 2364 avelumab (MSB0010718C), an anti‐PD‐L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer: a phase 1b trial. Eur J Cancer. 2015;51(suppl 3):S457.
- Disis ML, Patel MR, Pant S, et al. Avelumab (MSB0010718C; anti‐PD‐L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase 1b trial: safety and clinical activity. J Clin Oncol. 2016;34:5533.
- Hassan R, Thomas A, Patel MR, et al. Avelumab (MSB0010718C; anti‐PD‐L1) in patients with advanced unresectable mesothelioma from the JAVELIN Solid Tumor phase 1b trial: safety, clinical activity, and PD‐L1 expression. J Clin Oncol. 2016;34:8503.
- Kelly K, Heery CR, Patel MR, et al. Avelumab (MSB0010718C; anti‐PD‐L1) in patients with advanced cancer: safety data from 1300 patients enrolled in the phase 1b JAVELIN Solid Tumor trial. J Clin Oncol. 2016;34:3055.
- Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy‐refractory metastatic Merkel cell carcinoma: a multicentre, single‐group, open‐label, phase 2 trial. Lancet Oncol. 2016;17:1374‐1385.
- Kaufman HL, Russell JS, Hamid O, et al. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow‐up: JAVELIN Merkel 200, a phase 2 clinical trial. J Immunother Cancer. 2018;6:7.
- Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: John Wiley & Sons: 1980.
- Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti–PD‐1 antibody in cancer. N Engl J Med. 2012;366:2443‐2454.
- Patnaik A, Kang SP, Rasco D, et al. Phase I study of pembrolizumab (MK‐3475; anti‐PD‐1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res. 2015;21:4286‐4293.
- Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD‐1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677‐704.
- Rozali EN, Hato SV, Robinson BW, Lake RA, Lesterhuis WJ. Programmed death ligand 2 in cancer‐induced immune suppression. Clin Dev Immunol. 2012;2012:656340.
- Naidoo J, Page DB, Li BT, et al. Toxicities of the anti‐PD‐1 and anti‐PD‐L1 immune checkpoint antibodies. Ann Oncol. 2015;26:2375‐2391.
- Garon EB, Rizvi NA, Hui R, et al; KEYNOTE‐001 Investigators . Pembrolizumab for the treatment of non–small‐cell lung cancer. N Engl J Med. 2015;372:2018‐2028.
- Massard C, Gordon MS, Sharma S, et al. Safety and efficacy of durvalumab (MEDI4736), an anti‐programmed cell death ligand‐1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol. 2016;34:3119‐3125.
- Boyerinas B, Jochems C, Fantini M, et al. Antibody‐dependent cellular cytotoxicity activity of a novel anti‐PD‐L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res. 2015;3:1148‐1157.
- Fujii R, Friedman ER, Richards J, et al. Enhanced killing of chordoma cells by antibody‐dependent cell‐mediated cytotoxicity employing the novel anti‐PD‐L1 antibody avelumab. Oncotarget. 2016;7:33498‐33511.
- Wang C, Thudium KB, Han M, et al. In vitro characterization of the anti‐PD‐1 antibody nivolumab, BMS‐936558, and in vivo toxicology in non‐human primates. Cancer Immunol Res. 2014;2:846‐856.
- Sharon E, Streicher H, Goncalves P, Chen HX. Immune checkpoint inhibitors in clinical trials. Chin J Cancer. 2014;33:434‐444.
- Stewart R, Morrow M, Hammond SA, et al. Identification and characterization of MEDI4736, an antagonistic anti‐PD‐L1 monoclonal antibody. Cancer Immunol Res. 2015;3:1052‐1062.
- Nishijima TF, Shachar SS, Nyrop KA, Muss HB. Safety and tolerability of PD‐1/PD‐L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta‐analysis. Oncologist. 2017;22:470‐479.
- Chen R, Peng PC, Wen B, et al. Anti‐programmed cell death (PD)‐1 immunotherapy for malignant tumor: a systematic review and meta‐analysis. Transl Oncol. 2015;9:32‐40.
- Zhang T, Xie J, Arai S, et al. The efficacy and safety of anti‐PD‐1/PD‐L1 antibodies for treatment of advanced or refractory cancers: a meta‐analysis. Oncotarget. 2016;7:73068‐73079.
- De Velasco G, Je Y, Bosse D, et al. Comprehensive meta‐analysis of key immune‐related adverse events from CTLA‐4 and PD‐1/PD‐L1 inhibitors in cancer patients. Cancer Immunol Res. 2017;5:312‐318.
- Vogel WH. Infusion reactions: diagnosis, assessment, and management. Clin J Oncol Nurs. 2010;14:E10‐E21.
Source: PubMed